RHYTHM PHARMACEUTICALS INC (RYTM)

US76243J1051 - Common Stock

55.85  -0.19 (-0.34%)

After market: 55.85 0 (0%)

Fundamental Rating

2

Overall RYTM gets a fundamental rating of 2 out of 10. We evaluated RYTM against 565 industry peers in the Biotechnology industry. RYTM has a bad profitability rating. Also its financial health evaluation is rather negative. RYTM is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RYTM has reported negative net income.
RYTM had a negative operating cash flow in the past year.
RYTM had negative earnings in each of the past 5 years.
RYTM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -110.83%, RYTM is not doing good in the industry: 78.83% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -263.89%, RYTM is doing worse than 71.89% of the companies in the same industry.
Industry RankSector Rank
ROA -110.83%
ROE -263.89%
ROIC N/A
ROA(3y)-41.33%
ROA(5y)-48.24%
ROE(3y)-67.27%
ROE(5y)-66.47%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of RYTM (88.72%) is better than 91.46% of its industry peers.
RYTM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RYTM has more shares outstanding
The debt/assets ratio for RYTM is higher compared to a year ago.

2.2 Solvency

RYTM has an Altman-Z score of 2.99. This is not the best score and indicates that RYTM is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.99, RYTM is doing good in the industry, outperforming 75.09% of the companies in the same industry.
RYTM has a Debt/Equity ratio of 0.72. This is a neutral value indicating RYTM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.72, RYTM is not doing good in the industry: 76.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Altman-Z 2.99
ROIC/WACCN/A
WACC10.88%

2.3 Liquidity

A Current Ratio of 3.49 indicates that RYTM has no problem at all paying its short term obligations.
With a Current ratio value of 3.49, RYTM perfoms like the industry average, outperforming 42.17% of the companies in the same industry.
RYTM has a Quick Ratio of 3.34. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.34, RYTM is in line with its industry, outperforming 42.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.49
Quick Ratio 3.34

More info and screens

4

3. Growth

3.1 Past

RYTM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.54%.
Looking at the last year, RYTM shows a very strong growth in Revenue. The Revenue has grown by 123.45%.
EPS 1Y (TTM)-37.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.95%
Revenue 1Y (TTM)123.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.76%

3.2 Future

RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.49% yearly.
RYTM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 64.62% yearly.
EPS Next Y-38.62%
EPS Next 2Y8.46%
EPS Next 3Y19.59%
EPS Next 5Y30.49%
Revenue Next Year56.92%
Revenue Next 2Y50.63%
Revenue Next 3Y61.04%
Revenue Next 5Y64.62%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RYTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RYTM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RYTM's earnings are expected to grow with 19.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.46%
EPS Next 3Y19.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (12/24/2024, 7:36:24 PM)

After market: 55.85 0 (0%)

55.85

-0.19 (-0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-20 2025-02-20/amc
Inst Owners109.98%
Inst Owner Change-3.37%
Ins Owners0.6%
Ins Owner Change-0.28%
Market Cap3.43B
Analysts82.35
Price Target71.68 (28.34%)
Short Float %11.64%
Short Ratio12.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.12%
Min EPS beat(2)5.17%
Max EPS beat(2)11.07%
EPS beat(4)3
Avg EPS beat(4)2.84%
Min EPS beat(4)-6.55%
Max EPS beat(4)11.07%
EPS beat(8)5
Avg EPS beat(8)2.36%
EPS beat(12)8
Avg EPS beat(12)4.72%
EPS beat(16)10
Avg EPS beat(16)-25.64%
Revenue beat(2)1
Avg Revenue beat(2)-0.36%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)0.25%
Revenue beat(4)1
Avg Revenue beat(4)-3.12%
Min Revenue beat(4)-6.39%
Max Revenue beat(4)0.25%
Revenue beat(8)3
Avg Revenue beat(8)3.48%
Revenue beat(12)5
Avg Revenue beat(12)19.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.89%
PT rev (3m)18.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.79%
EPS NY rev (1m)1.39%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)1.66%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.78
P/FCF N/A
P/OCF N/A
P/B 22.48
P/tB 23.46
EV/EBITDA N/A
EPS(TTM)-4.47
EYN/A
EPS(NY)-2.64
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS2.25
BVpS2.48
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.83%
ROE -263.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.72%
FCFM N/A
ROA(3y)-41.33%
ROA(5y)-48.24%
ROE(3y)-67.27%
ROE(5y)-66.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.49
Quick Ratio 3.34
Altman-Z 2.99
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)18.84%
Cap/Depr(5y)99.08%
Cap/Sales(3y)4.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.95%
EPS Next Y-38.62%
EPS Next 2Y8.46%
EPS Next 3Y19.59%
EPS Next 5Y30.49%
Revenue 1Y (TTM)123.45%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.76%
Revenue Next Year56.92%
Revenue Next 2Y50.63%
Revenue Next 3Y61.04%
Revenue Next 5Y64.62%
EBIT growth 1Y-118.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.68%
EBIT Next 3Y9.73%
EBIT Next 5YN/A
FCF growth 1Y30.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.84%
OCF growth 3YN/A
OCF growth 5YN/A